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Abstract
Background: Calretinin is one of the well-established immunohistochemical markers in the diagnostics of malignant 
mesothelioma (MM). Its utility as a diagnostic tool in human blood, however, is scarcely investigated. The aim of this 
study was to develop an enzyme-linked immunosorbent assay (ELISA) for human calretinin in blood and to assess its 
usefulness as a potential minimally invasive diagnostic marker for MM.
Methods: Initially, attempts were made to establish an assay using commercially available antibodies and to optimize 
it by including a biotin-streptavidin complex into the assay protocol. Subsequently, a novel ELISA based on polyclonal 
antibodies raised in rabbit immunized with human recombinant calretinin was developed. The assay performance in 
human serum and plasma (EDTA/heparin) and the influence of calcium concentrations on antibody recognition were 
studied. Stability of spiked-in calretinin in EDTA plasma under different storage conditions was also examined. In 
preliminary studies serum and plasma samples from 97 healthy volunteers, 35 asbestos-exposed workers, and 42 MM 
patients were analyzed.
Results: The mean detection range of the new ELISA was 0.12 to 8.97 ng/ml calretinin. The assay demonstrated 
markedly lower background and significantly higher sensitivity compared to the initially contrived assay that used 
commercial antibodies. Recovery rate experiments confirmed dependence of calretinin antibody recognition on 
calcium concentration. Calcium adjustment is necessary for calretinin measurement in EDTA plasma. Spiked-in 
calretinin revealed high stability in EDTA plasma when stored at room temperature, 4°C, or after repeated freeze/thaw 
cycles. Median calretinin values in healthy volunteers, asbestos workers, and MM patients were 0.20, 0.33, and 0.84 ng/
ml, respectively (p < 0.0001 for healthy vs. MM, p = 0.0036 for healthy vs. asbestos-exposed, p < 0.0001 for asbestos-
exposed vs. MM). Median values in patients with epithelioid and biphasic MM were similar. No influence of age, gender, 
smoking status, or type of medium (plasma/serum) on calretinin values was found.
Conclusions: The novel assay is highly sensitive and applicable to human serum and plasma. Calretinin appears to be 
a promising marker for the blood-based detection of MM and might complement other markers. However, further 
studies are required to prove its usefulness in the diagnosis of MM patients.
Background
Malignant mesothelioma (MM) is a highly aggressive
tumor of the serous membranes. MM is associated with
asbestos exposure and will remain a major health prob-
lem on a worldwide scale for many decades [1,2]. Diagno-
sis of MM usually occurs at late stages of the disease
when treatment is very difficult. There is an urgent need
for markers for early diagnosis that may improve treat-
m e n t  o p t i o n s.  T o  l i m i t  i n v a s i v e  d i a g n o s t i c  p r o c e d u r e s,
blood-based markers would be preferable. Up to now, sol-
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uble mesothelin-related peptides (SMRP) remains,
despite of its low sensitivity, the best available serum
marker for MM [3-5]. A marker with similar potential is
the related N-ERC/mesothelin [6]. While a single tumor
marker might not reach sufficient sensitivity and specific-
ity, there is evidence that a panel of several markers could
substantially improve diagnosis of cancer [7]. Moreover,
reliable and non-invasive tools such as blood markers for
screening of high-risk, asbestos-exposed populations are
still needed.
Based on immunohistochemical results, such a poten-
tial candidate marker might be calretinin. Calretinin (cal-
bindin 2, CALB2) is a 29 kDa calcium-binding protein, a
member of the so-called EF-hand protein family fre-
quently found in neurons [8]. It was suggested that calre-
tinin plays a role in intracellular Ca2+ homeostasis and
buffering [9]. It was shown that calretinin down-regula-
tion blocks the cell cycle and increases apoptosis in the
colon adenocarcinoma cell line WiDr [10]. Recently,
Henzi et al. presented evidence that calretinin plays a role
i n  c e l l  s u rv i v a l  d u r i n g  a s b e stos exposure. However, its
exact role in neoplasia remains unknown [11]. The pres-
ence of calretinin was also demonstrated in several other
organs and tissues, among them in mesothelium [12].
Since the first evaluation of calretinin as an immunohis-
tochemical marker of MM [13], several studies have dem-
onstrated the significance of calretinin as a reliable
marker for the diagnosis of MM, based on its high sensi-
tivity (up to 100%) and specificity (up to 87.5%) in tumor
tissues [14-17].
The relevance of calretinin as a potential blood marker
for minimally invasive diagnostics of MM has not yet
been investigated. Schwaller et al. described calretinin
detection in human serum from cancer patients (e.g.,
ovarian, breast, lung), using a sandwich ELISA [18,19].
However, no sera from patients with MM were analyzed
i n  t h i s  s t u d y  a n d ,  t o  o u r  b e s t  k n o w l e d g e ,  n o  f u r t h e r
attempts to determine calretinin in serum or plasma were
undertaken.
Thus, the purpose of this study was to develop and
optimize a novel polyclonal antibody-based ELISA for
human calretinin, to test its application in human serum
and plasma, and to perform a first assessment of its
potential usefulness as a blood test for the diagnostic of
MM.
Methods
Human serum and plasma samples
Serum (n = 65) or EDTA plasma samples (n = 32) were
collected from 97 healthy volunteers including 54 men
(mean age 45 years; range 25-76 years) and 43 women
(mean age 41 years; range 25-74 years), and stored at -
80°C until use. In addition to serum samples five volun-
teers also provided EDTA and heparin plasma samples.
The 97 volunteers were recruited from employees and
former employees of the IPA and the associated clinic
and, based on routine occupational-medical examina-
tions, were determined to be apparently healthy. Plasma
(n = 10) and serum (n = 25) samples of one female and 34
male workers formerly exposed to asbestos and without
evidence of neoplasia (mean age 69, range 55-83 years)
were obtained at the IPA and the participating clinics and
study centers. The asbestos-exposed group comprised
persons without and with benign diseases like pleural
plaques or asbestosis, representative of a group of high-
risk subjects. Serum and plasma samples (n = 27 and 15,
respectively) from 31 men and 11 women with MM
(mean age 67 years, range 35-85 years) were analyzed as
well. Samples of MM patients were either purchased from
conbio (Kiel, Germany) or obtained from the French and
German clinics and study centers associated with the
study. Histology was known for 32 of the MM cases, with
19 epithelioid, 1 sarcomatoid, and 12 biphasic tumors.
Blood samples of MM patients were collected before any
anti-tumor treatment. All participants provided written
informed consent and permission for the study was
obtained from the ethics committee of the Ruhr-Univer-
sity Bochum (reference number 3217-08) or of the Hospi-
tal of the University of Lille II, France.
Preparation of anti-calretinin antibodies
For the immunization of a rabbit 0.4 mg human recombi-
nant calretinin (Swant, Belinzona, Switzerland) in Titer-
Max™ Gold as an adjuvant was injected. In intervals of
five to six weeks, the rabbit was boostered twice with 0.4
mg calretinin emulsified with T iterMax™ Gold and was
bled four weeks after each boost to check the titer by
analysis of the serum. Four months after primary immu-
nization the final antiserum was obtained.
The rabbit serum containing polyclonal anti-calretinin
antibodies was loaded via FPLC (Pharmacia, Uppsala,
Sweden) on a protein G column (GE Healthcare, Munich,
Germany), washed with phosphate-buffer (20 mM, pH 7)
and eluted with glycine-HCl-buffer (pH 2.8). Eluted frac-
tions were neutralized directly with 1/10 volume 1 M
Tris-HCl-buffer (pH 9), pooled and dialyzed. Protein
concentration determined by BSA protein assay (Bio-Rad
Laboratories GmbH, Munich, Germany) was 0.9 mg/ml.
Aliquots of the purified antibodies were stored at -80°C.
The purified polyclonal anti-calretinin antibodies were
biotinylated by mixing with a 33-fold molar excess of bio-
tin-N-hydroxysuccinimid-ester (Roche Diagnostics
GmbH, Mannheim, Germany) dissolved in dimethylsul-
foxid and incubated under continuous agitation for 4 h at
room temperature (RT). The biotinylated antibodies were
dialyzed extensively and stored in aliquots at -80°C.Raiko et al. BMC Cancer 2010, 10:242
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Development of a two-site polyclonal antibody-based 
ELISA
Assay variant 1 was based on the calretinin sandwich
ELISA described previously by Schierle et al. with several
modifications [18]. Microtiter plates (MaxiSorp, Nunc,
Denmark) were coated with goat polyclonal antibodies to
calretinin (CG1; Swant, Belinzona, Switzerland) diluted
1:200 in 0.1 M carbonate/bicarbonate buffer, pH 9.6 (0.5
μg/well), and incubated overnight at 4°C. The plates were
blocked with 1.5% (w/v) casein in PBS (200 μl/well) for
120 min at RT (all incubations at RT were carried out
under shaking) and then washed three times with PBST
(PBS containing 0.05% Tween 20). Human purified
recombinant calretinin (Swant) was used as standard. A
stock solution (200 μg/ml) was serially diluted in PBST to
give calretinin amounts from 2000 to 0.061 ng/ml. After
90 min incubation at RT followed by washing, rabbit
polyclonal antibodies to calretinin (7699/4; Swant),
diluted 1:1000 with PBST (0.1 μg/well), were added and
plates were incubated for another 90 min. Then, goat
anti-rabbit IgG peroxidase conjugate (Sigma, Saint Louis,
MO, USA), diluted 1:10000 in PBST, was added to the
washed plates. After 90 min incubation and washing 100
μl/well of Enhanced K-Blue TMB Substrate (Neogen Cor-
poration, Lexington, KY, USA) was added. The color
development was stopped by the addition of 100 μl 1 M
sulphuric acid per well and absorbance was measured at
450 nm using an automated plate reader (Molecular
Devices, Sunnyvale, CA, USA).
In order to improve the assay's sensitivity, other modifi-
cations were applied. In assay variant 2 rabbit polyclonal
antibodies to calretinin were used as capture antibody
(dilution 1:300 in carbonate/bicarbonate buffer, pH 9.6).
The plates were incubated overnight at 4°C, blocked for
120 min at RT and washed three times. Serially diluted
calretinin standard (concentrations from 50 to 0.391 ng/
ml) was added and plates were incubated overnight at
4°C. After washing the plates were incubated for 90 min
with 1:1000 diluted goat polyclonal antibodies and
washed again. 60 min after addition of 1:20000 diluted
rabbit anti-goat IgG-biotin conjugate (Sigma, Saint Louis,
MO, USA) the plates were washed three times and incu-
bated for another 60 min with horseradish-peroxidase-
streptavidin conjugate (dilution 1:20000, Fitzgerald
Industries International, Concord, MA, USA). After final
washing 100 μl/well of ABTS substrate solution (2.2'-
azino-bis(3-ethyl-benzthiazoline-6-sulfonic acid), Sigma,
Taufkirchen, Germany) were added. The substrate was
activated with H2O2  according to the manufacturer's
instructions. The enzyme reaction was stopped with 100
μl/well 0.32% NaF and absorbance was measured at 414
nm.
Novel sandwich ELISA using self-developed polyclonal 
antibodies to calretinin
Assay variant 3 was generated with self-developed puri-
fied and biotinylated rabbit polyclonal antibodies to
human recombinant calretinin. Microtiter plates were
coated with purified polyclonal antibodies (100 μl/well,
dilution 1:1500; 0.6 μg/ml; 100 mM carbonate/bicarbon-
ate buffer, pH 9.6) and allowed to adhere overnight at 4°C.
They were then blocked with 1.5% casein, washed and
incubated with dilutions of the standard and samples for
1 h at RT. A stock solution of human purified recombi-
nant calretinin was diluted in PBST to give standard con-
centrations between 10 and 0.08 ng/ml. Next, plates were
washed three times and incubated for 1 h with biotiny-
lated polyclonal antibodies (100 μl/well, dilution 1:5000;
0.18 μg/ml). After washing 100 μl/well of 1:20000 diluted
horseradish-peroxidase-streptavidin conjugate (Fitzger-
ald Industries International, Concord, MA, USA) was
added. One hour later plates were washed and 100 μl with
H2O2-activated ABTS substrate solution was added to
each well. The enzyme reaction was stopped by addition
of 100 μl 0.32% NaF and absorbance was read at 414 nm.
The dose-response curves for standards were obtained
by 4-parameter curve fitting using SoftMax Pro 4.7.1
from Molecular Devices. The lower detection limit of the
assay was defined by adding 0.1 OD units (rounded 8-fold
mean of the standard deviation of background values
from eight plates) to the background value of each plate.
Calretinin amounts above that value were considered
detectable.
Calretinin recovery rate experiments
Calretinin recovery rates were studied in serum, EDTA
plasma, and heparin plasma from healthy individuals.
Calretinin concentrations in all these samples were below
the detection limit and were called calretinin-negative. In
these experiments recovery rates were examined in the
presence of various calcium concentrations from 2.5 to
10 mM in dilution buffer (TBST: Tris-buffered saline, pH
7.4 containing 0.05% Tween 20). In addition, the influ-
ence of various added calretinin concentrations on its
recovery rate in plasma or serum was also studied. Prior
to addition of calcium to EDTA plasma, heparin was
added to a final concentration of 25 U/ml to avoid poten-
tial coagulation after calcium adjustment.
Stability of spiked-in calretinin was studied in EDTA
plasma samples from five healthy calretinin-negative
individuals. Calretinin (5 ng/ml final concentration) and
heparin (25 U/ml plasma) were spiked into each plasma
aliquot. Aliquots were handled in four different ways: 5
days at RT, 5 days at 4°C, 5 days at -80°C and 10 freeze/
thaw cycles within 5 days. Afterwards, they were dilutedRaiko et al. BMC Cancer 2010, 10:242
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1:5 with 5 mM CaCl2 in dilution buffer (TBST) and the
calretinin recovery rate was measured.
Statistical analysis
Nonparametric Mann Whitney's U test and Kruskal-Wal-
lis test for data comparison were performed with Graph-
Pad Prism (GraphPad Software Inc., San Diego, CA
USA). P < 0.05 was considered statistically significant.
Pearson's correlation coefficient was calculated with SAS
(SAS Institute Inc., Cary, North Carolina, USA, Version
9.2) to determine the correlation between age and calreti-
nin values. The graphs were created with GraphPad
Prism and SigmaPlot 8 (Systat Software Inc., San Jose,
CA, USA). Values below standard range of the assay were
set to a fixed value based on the four-parameter fit of the
standard curve of each run.
Results
Initially, we have used commercially available antibodies
to establish a new calretinin assay. This assay was based
on the only published calretinin ELISA, which was devel-
oped by Schierle et al. [19]. Goat anti-calretinin was used
as capture antibody and rabbit anti-calretinin as detec-
tion antibody. This assay had a high background and a
lower detection limit of 5.41 ng/ml (Fig. 1, variant 1). All
attempts to improve its sensitivity and to reduce the
background failed. An inversion of capture and detection
antibodies (rabbit antibodies for capturing and goat anti-
bodies for detection) had no significant effect either (data
not shown). Furthermore, a biotin-streptavidin complex
was included in the assay protocol. Although the back-
ground was lower than in assay variant 1, it still remained
high. The lower detection limit of 0.48 ng/ml was almost
tenfold lower than that of variant 1 indicating an
improved sensitivity of variant 2 (Fig. 1, variant 2).
Finally, human recombinant calretinin was used to raise
polyclonal anti-calretinin antibodies in rabbit. These
antibodies were purified and utilized for calretinin cap-
turing. One part of the purified antibodies was biotiny-
lated and used for calretinin detection. Various
concentrations of antibodies were tested to yield an opti-
mized assay protocol. A representative standard curve is
shown in Fig. 1 (assay variant 3). The novel ELISA dem-
onstrated noticeably lower background and higher sensi-
tivity than variants 1 and 2. Its lower detection limit of
0.12 ± 0.05 ng/ml (n = 11) was approximately 46-fold and
4-fold lower compared with variants 1 and 2, respectively.
Also, the concentrations of the antibodies were consider-
ably lower than those in variants 1 and 2. The optimized
antibody dilutions of capture and detection antibodies
were 1:1500 and 1:5000, respectively (0.6 μg/ml and 0.18
μg/ml, respectively). In this combination the assay had a
mean detection range of 0.12 to 8.97 ng/ml (n = 11).
Calretinin recovery rates were studied initially in EDTA
plasma of five healthy volunteers using assay variant 3. All
samples revealed no measurable calretinin in preliminary
examinations and were regarded as calretinin-negative.
As calretinin is a Ca2+-binding protein its antibody recog-
nition depends on Ca2+ in the medium [20-22]. There-
fore, the influence of various Ca2+  concentrations in
EDTA plasma on its recovery rate was studied. In addi-
tion, the influence of plasma dilutions was analyzed. In
these experiments a pool of calretinin-negative EDTA
plasmas was diluted 1:2, 1:3, 1:4, and 1:5 either with
TBST or with TBST containing increasing concentra-
tions of CaCl2. The recovery rate of 5 ng/ml calretinin
was measured for each combination of Ca2+ concentra-
tion and plasma dilution. As shown in Fig. 2A, without
calcium addition all plasma dilutions exhibited calretinin
recovery rates of just 15%. To reach a maximal recovery
rate in 1:2 diluted plasma 7.5 mM CaCl2, in 1:3 diluted
plasma 5 mM CaCl2, and in 1:4 and 1:5 diluted plasma 2.5
mM CaCl2 were necessary. Recovery rates of calretinin
were slightly better in higher diluted plasmas. As a conse-
quence of these results, most of the following experi-
ments were performed in 1:5 diluted plasma or serum
samples and 5 mM CaCl2 was considered to be a suffi-
cient concentration for calcium adjustment in EDTA
plasma. Additionally, the influence of different spiked-in
calretinin concentrations on its recovery rate was ana-
lyzed. As shown in Fig. 2B, the spiked-in calretinin con-
centrations from 0.625 to 5 ng/ml revealed almost the
same recovery rates, about 20-23% without calcium and
about 86-99% with calcium adjustment. An improvement
of the recovery rate in EDTA-plasma after calcium
adjustment was observed also with assay variant 2 (data
not shown).
Figure 1 Standard curves of calretinin enzyme-linked immuno-
sorbent assay (ELISA) systems. Assay variant 1: Capture and detec-
tion antibodies based on Schierle et al. [18]. Assay variant 2: 
Modification of variant 1 with inversion of capture and detection anti-
bodies and amplification by a biotin-streptavidin complex. Assay vari-
ant 3: Sandwich ELISA with novel polyclonal anti-calretinin rabbit IgG 
antibody for capturing and detection (biotinylated).Raiko et al. BMC Cancer 2010, 10:242
http://www.biomedcentral.com/1471-2407/10/242
Page 5 of 8
In order to examine the influence of different media on
calretinin antibody recognition, recovery rates were stud-
ied in calretinin-negative sera and plasma samples (EDTA
and heparin) from the same healthy individuals. Samples
were diluted 1:5 either with TBST or with 5 mM CaCl2 in
TBST and 5 ng/ml calretinin was spiked-in to each sam-
ple. The resulting recovery rates are shown in Fig. 2C.
They were 89.9 ± 12.9% and 92.2 ± 15.7% (n = 11) in
serum and heparin plasma, respectively. Similar results
were obtained with lower added calretinin concentrations
(0.625, 1.25, and 2.5 ng/ml). Calcium addition revealed no
influence on the antibody recognition of calretinin in
serum and heparin plasma (data not shown). Like in the
experiments with EDTA plasma dilutions, recovery rates
in EDTA plasma samples without calcium addition were
low (21.3 ± 5.0%). In EDTA plasma resupplied with cal-
cium, however, they were comparable with those in
serum and heparin plasma (96.1 ± 15.5%).
Spiked-in calretinin revealed a high stability when
stored for 5 days at -80°C, 4°C, or even RT. Likewise, up to
10 freeze/thaw cycles had no significant influence on its
recovery rate. The measured values of calretinin were
from 4.9 to 5.1 ng/ml and its recovery rates were about
100% (data not shown).
In a preliminary assessment of calretinin as a possible
tumor marker its concentrations were measured in 1:2 to
1:4 diluted sera from healthy subjects (n = 65) and from
patients with diagnosed MM (n = 27) as well as in 1:5
diluted EDTA plasmas (32 healthy subjects and 15
patients with MM). As shown in Fig. 3, the median values
of calretinin in serum and plasma of MM patients were
significantly higher than in blood samples from healthy
controls (0.84 vs. 0.20 ng/ml; p < 0.0001) or from asbes-
tos-exposed workers (0.84 vs. 0.33 ng/ml; p < 0.0001).
There was also a significant difference between calretinin
blood levels in asbestos-exposed workers versus healthy
controls (0.33 vs. 0.20 ng/ml, respectively; p = 0.0036).
Regarding the histological MM subtype, patients with
epithelioid MM did not exhibit significantly different
m e d i a n  s e r u m  l e v e l s  o f  c a l r e t i n i n  t h a n  p a t i e n t s  w i t h
biphasic MM (0.87 vs. 0.90 ng/ml, respectively; p = 0.41)
(Fig. 4). Because we had only one sarcomatoid MM in our
collective, a meaningful statistical analysis for this sub-
type was not possible. Median calretinin values in serum
vs. plasma revealed no significant differences within the
group of healthy controls (0.19 vs. 0.21 ng/ml, respec-
tively; p = 0.69), asbestos-exposed workers (0.31 vs. 0.42
ng/ml, respectively; p = 0.55), or MM patients (0.77 vs.
1.02 ng/ml, respectively; p = 0.96). There was no signifi-
cant difference in the median blood calretinin value in
the healthy subjects group, depending on their age (Pear-
son's correlation coefficient, r = -0.11; p = 0.27), their sex
(men vs. women: 0.21 vs. 0.20 ng/ml; p = 0.56), or their
smoking status (smokers (n = 11), ex-smokers (n = 11),
and non-smokers (n = 45): 0.23, 0.23, and 0.21 ng/ml
respectively; p = 0.83).
Discussion
Calretinin is one of the best and most frequently used
markers in the immunohistochemical diagnosis of MM
[17,23]. Its value as a blood-based tumor marker in MM
Figure 2 Calretinin recovery experiments. (A) Influence of EDTA 
plasma dilution and calcium concentration on calretinin recovery rate 
(5 ng/ml spiked-in calretinin). (B) Recovery rates of various spiked-in 
calretinin concentrations in EDTA plasma (n = 9). Plasma dilution 1:5, 5 
mM CaCl2 in dilution buffer. (C) Calretinin recovery rates in serum, ED-
TA, and heparin plasma (n = 11). 5 ng/ml spiked-in calretinin, dilution 
1:5, 5 mM CaCl2 in dilution buffer.Raiko et al. BMC Cancer 2010, 10:242
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remains to be proven. A minimally invasive blood marker
would greatly improve diagnosis and early detection of
MM. Schwaller et al. detected calretinin and its splice
form calretinin-22k in sera from patients with tumors of
various localizations as well as from healthy persons [19].
Although the calretinin values in the patient group were
considerably higher than in the control group, the rela-
tively low number of samples in each category did not
allow for an association with the pathological condition.
To our knowledge, no other studies to assess soluble cal-
retinin in human blood have been performed yet.
To develop a novel sandwich ELISA, we have used poly-
clonal antibodies raised in rabbit after injection of human
recombinant calretinin. Compared to assay variants 1 and
2 with commercial antibodies, the novel assay is repro-
ducible, provides higher sensitivity (about 46 and 4 times
higher than those of variants 1 and 2, respectively), has
noticeably lower background, and exhibits a steeply rising
calibration curve. In the assay variants 1 and 2 capture
and detection antibodies are polyclonal and were raised
in different species (rabbit and goat, respectively). To
facilitate a final enzyme reaction in these assay variants, a
labeled secondary antibody against the detection anti-
body was used (e.g., goat anti-rabbit IgG peroxidase con-
jugate in variant 1). Although this secondary antibody
was raised in the same species as the capture one (goat in
variant 1), it revealed some non-specific binding to the
latter (data not shown). The high background observed in
the assay variants 1 and 2 was partially caused by this
non-specific binding. In the novel ELISA we have used
biotinylated anti-calretinin as a detection antibody,
thereby a labeled secondary detection antibody was dis-
Figure 3 Calretinin levels in blood samples. Individual values for calretinin in healthy subjects (n = 97), persons with previous asbestos exposure (n 
= 35), and patients with malignant mesothelioma (n = 42). Open circles represent serum, filled circles plasma samples. Bars indicate median marker 
levels. Differences between all groups were significant (p < 0.0001 for healthy vs. MM, p = 0.0036 for healthy vs. asbestos-exposed, p < 0.0001 for as-
bestos-exposed vs. MM).
Figure 4 Calretinin levels and histological subtypes. Values of cal-
retinin in blood samples of patients with epithelioid (n = 19) and bi-
phasic MM (n = 12). Bars indicate median marker levels. The difference 
between the two subtypes was not significant (p = 0.41).Raiko et al. BMC Cancer 2010, 10:242
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pensable. The background of this assay variant is signifi-
cantly lower, supporting our explanation of the high
background in assay variants 1 and 2. Furthermore, the
novel assay has fewer steps and requires less time. In
addition, considerably lower concentrations of capture
and detection antibodies are required for its performance
(0.6 μg/ml and 0.18 μg/ml compared to 5 μg/ml and 1 μg/
ml for variant 1, respectively) and therefore it is less
expensive.
The choice of appropriate sample type (serum or
plasma) and anticoagulant (EDTA, heparin, or citrate) is
of great importance for the practical use of assays. Until
now calretinin concentration in human blood was deter-
mined only in serum samples [19]. In the present study
we investigated for the first time calretinin values in
E D T A  a n d  h e p a r i n  p l a s m a  a s  w e l l  a s  i n  s e r u m ,  u s i n g
recovery rate experiments.
In our initial studies we have observed very low recov-
ery rates of spiked-in calretinin in EDTA plasma (15-
20%). They were clearly improved after addition of CaCl2
to the dilution buffer. Similar effects were described for
the ELISA-based detection of S100A12 in EDTA plasma,
another Ca2+-binding protein of the EF-hand family [24].
It is known that calretinin antibody recognition depends
on its Ca2+-binding status and it was experimentally con-
firmed that Ca2+ induces conformational changes in the
calretinin molecule that likely promote antibody recogni-
tion [20-22]. These findings explain the initially low
recovery rates observed in our experiments, because
EDTA strongly binds calcium so that the remaining con-
centration in plasma is not sufficient to provide appropri-
ate conformational changes necessary for optimal
antibody recognition. Subsequently, we found a Ca2+ con-
centration in the dilution buffer of 5 mM in combination
with a plasma dilution of 1:5 to be optimal. Also, due to
the lower viscosity of diluted plasma antibody recogni-
tion is less impeded and assay reproducibility is thus
improved.
Despite rules for proper tissue banking, in reality sam-
ples might not always be handled according to standard
operating procedures, leading to altered marker levels
[25]. Our present study indicates that calretinin concen-
tration in plasma is not altered after repeated freeze/thaw
cycles or during the storage at RT or 4°C for at least five
days. These results suggest that calretinin might be a sta-
ble marker applicable in field studies.
Using our sandwich ELISA, we determined calretinin
l e v e l s  i n  s e r u m  a n d  E D T A  p l a s m a  f r o m  p a t i e n t s  w i t h
MM, asbestos-exposed persons (with and without benign
lung or pleural diseases), and healthy controls. Signifi-
cantly higher values were observed in MM samples com-
pared to samples of healthy volunteers or asbestos-
exposed persons without malignancies. This result - after
confirmation in a larger group of patients - may suggest
blood calretinin as a soluble marker for the (early) diag-
nosis of MM.
Current MM markers such as soluble mesothelin
(SMRP) mainly detect epithelioid MM, while biphasic
and especially sarcomatoid MM are frequently missed.
Based on immunohistochemistry, calretinin is known to
be detected in epithelioid MM but can also be found in
other MM subtypes [13,17]. Our results indicate that this
finding - at least for epithelioid and biphasic MM - could
be extended to the detection of this marker in blood sam-
ples.
On the basis of our initial results we suggest that the
measurement of calretinin in human serum and plasma
might be a useful marker for the diagnosis of MM, alone
or combined with other markers such as soluble meso-
thelin. However, these results are based on relatively
small numbers and further studies on more patients,
including subgroups of subjects with other tumors and
non-malignant lung or pleural diseases, are needed to
confirm our initial data. Such a study is presently ongo-
ing. In addition, to validate a new marker for early detec-
t i o n  o f  c a n c e r  t h e  m o s t  s u i t a b l e  d e s i g n  i s  t h a t  o f  a
prospective study. Currently, we are establishing a large
cohort of patients with benign asbestos-related diseases
to evaluate calretinin and other potential markers within
a longitudinal study.
Conclusions
We have developed a novel and sensitive ELISA for the
detection of calretinin in serum, heparin plasma, or
EDTA plasma augmented with calcium. No significant
differences between calretinin recovery rates in serum or
plasma were detected. Also, high calretinin stability was
observed under several storage conditions as well as after
repeated freeze/thaw cycles. Calretinin levels were signif-
icantly increased in MM patients, suggesting that it might
be suitable - possibly in combination with other markers
like mesothelin - for the blood-based detection of MM.
These factors provide a promising basis for the validation
of calretinin as a biomarker for MM in larger case-control
as well as prospective studies.
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